Pages that link to "Q37976344"
Jump to navigation
Jump to search
The following pages link to Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence (Q37976344):
Displaying 50 items.
- Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis (Q26852672) (← links)
- Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis (Q28066677) (← links)
- Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study (Q28546799) (← links)
- The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis (Q30730505) (← links)
- Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients (Q33764067) (← links)
- Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study (Q33883508) (← links)
- GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation. (Q34065039) (← links)
- Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study (Q35091777) (← links)
- Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial (Q35136988) (← links)
- Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis (Q35446549) (← links)
- Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review (Q36147567) (← links)
- Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy (Q36501690) (← links)
- Interferon beta and glatiramer acetate therapy (Q36568660) (← links)
- Can we prevent or treat multiple sclerosis by individualised vitamin D supply? (Q36588696) (← links)
- Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? (Q36648907) (← links)
- Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment (Q36698871) (← links)
- A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod (Q36787755) (← links)
- Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines (Q36956515) (← links)
- Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis (Q36975701) (← links)
- Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey (Q37027674) (← links)
- Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort® devices (Q37300902) (← links)
- ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study (Q37320927) (← links)
- Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis (Q37668556) (← links)
- Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice (Q37684523) (← links)
- Mesenchymal stem cells as treatment for MS - progress to date. (Q38057682) (← links)
- RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence (Q38068514) (← links)
- From Identification to Characterization of the Multiple Sclerosis Susceptibility Gene CLEC16A. (Q38084534) (← links)
- Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. (Q38111620) (← links)
- Fingolimod for the treatment of relapsing multiple sclerosis (Q38112209) (← links)
- Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine (Q38218692) (← links)
- Fostering adherence to injectable disease-modifying therapies in multiple sclerosis (Q38238548) (← links)
- PEGylated IFNβ-1a in the treatment of multiple sclerosis. (Q38513495) (← links)
- Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study. (Q38631863) (← links)
- Treatment selection and experience in multiple sclerosis: survey of neurologists (Q38662141) (← links)
- The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis (Q38761495) (← links)
- The future of multiple sclerosis treatments. (Q38808485) (← links)
- Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. (Q39021942) (← links)
- Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis (Q39234479) (← links)
- Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis (Q39672574) (← links)
- Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA. (Q41256768) (← links)
- Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. (Q44954206) (← links)
- Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial. (Q46604857) (← links)
- Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy. (Q47116956) (← links)
- Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. (Q48058748) (← links)
- Treatment of pediatric multiple sclerosis. (Q53609248) (← links)
- Treatment satisfaction and quality of life in patients treated with fingolimod. (Q55314123) (← links)
- Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study (Q64116166) (← links)
- Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain (Q64227872) (← links)
- Therapeutic Interferon Interchange in Relapsing Multiple Sclerosis Lowers Health Care and Pharmacy Expenditures with Comparable Safety. (Q64975333) (← links)
- Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon β-1a. (Q64988430) (← links)